Advertisement

Drugs & Therapy Perspectives

, Volume 35, Issue 9, pp 413–417 | Cite as

Some phytomedicines show promise for the management of migraine, but further clinical evidence is needed before they can be strongly recommended

  • Adis Medical WritersEmail author
Disease Management
  • 15 Downloads

Abstract

Phytomedicines may provide new options for migraine prophylaxis and treatment based on their historical use and pharmacological properties. However, as clinical data are limited, no phytomedicine can currently be strongly recommended to manage migraine. Feverfew and butterbur may be effective in preventing migraine, but the efficacy of butterbur has been overshadowed by reports of severe petasites hepatotoxicity. Although further research is needed, chamomile, coriander, peppermint and ginkgo have shown encouraging results in explorative clinical studies, and the active components of cannabis and St John’s wort have shown promise in preclinical studies.

Notes

Compliance with ethical standards

Conflict of interest

The article was adapted from CNS Drugs 2019; 33(5):399–415 [5] by employees of Adis International Ltd./Springer Nature, who are responsible for the article content and declare no conflicts of interest.

Funding

The preparation of this review was not supported by any external funding.

References

  1. 1.
    Noseda R, Burstein R. Migraine pathophysiology: anatomy of the trigeminovascular pathway and associated neurological symptoms, cortical spreading depression, sensitization, and modulation of pain. Pain. 2013;154(Suppl 1):S44–53.CrossRefPubMedGoogle Scholar
  2. 2.
    Burstein R, Noseda R, Borsook D. Migraine: multiple processes, complex pathophysiology. J Neurosci. 2015;35:6619–29.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Headache Classification Committee of the International Headache Society. The international classification of headache disorders, 3rd edition. Cephalalgia. 2018;38:1–211.Google Scholar
  4. 4.
    Goadsby PJ, Holland PR, Martins-Oliveira M, et al. Pathophysiology of migraine: a disorder of sensory processing. Physiol Rev. 2017;97:553–622.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Rajapakse T, Davenport WJ. Phytomedicines in the treatment of migraine. CNS Drugs. 2019;33(5):399–415.CrossRefPubMedGoogle Scholar
  6. 6.
    Levy D, Burstein R, Kainz V, et al. Mast cell degranulation activates a pain pathway underlying migraine headache. Pain. 2007;130:166–76.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    De Weerdt CJ, Bootsma HP, Hendriks H. Herbal medicines in migraine prevention randomized double-blind placebo-controlled crossover trial of a feverfew preparation. Phytomedicine. 1996;3(3):225–30.CrossRefPubMedGoogle Scholar
  8. 8.
    Pfaffenrath V, Diener HC, Fischer M, et al. The efficacy and safety of Tanacetum parthenium (feverfew) in migraine prophylaxis: a double-blind, multicentre, randomized placebo-controlled dose-response study. Cephalalgia. 2002;22(7):523–32.CrossRefPubMedGoogle Scholar
  9. 9.
    Diener HC, Pfaffenrath V, Schnitker J, et al. Efficacy and safety of 6.25 mg t.i.d. feverfew CO2-extract (MIG-99) in migraine prevention—a randomized, double-blind, multicentre, placebo-controlled study. Cephalalgia. 2005;25:1031–41.CrossRefPubMedGoogle Scholar
  10. 10.
    Murphy JJ, Heptinstall S, Mitchell JR. Randomised double-blind placebo-controlled trial of feverfew in migraine prevention. Lancet. 1988;2:189–92.CrossRefPubMedGoogle Scholar
  11. 11.
    Palevitch D, Earon G, Carasso R. Feverfew (Tanacetum parthenium) as a prophylactic treatment for migraine: a double-blind placebo-controlled study. Phytother Res. 1997;11:508–11.CrossRefGoogle Scholar
  12. 12.
    Holland S, Silberstein SD, Freitag F, et al. Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012;78:1346–53.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Pringsheim T, Davenport WJ, Mackie G, et al. Canadian Headache Society guideline for migraine prophylaxis. Can J Neurol Sci. 2013;40(5 Suppl 3):S1–80.PubMedGoogle Scholar
  14. 14.
    Evers S, Afra J, Frese A, et al. EFNS guideline on the drug treatment of migraine–revised report of an EFNS task force. Eur J Neurol. 2009;16(9):968–81.CrossRefPubMedGoogle Scholar
  15. 15.
    McGuffin M. American Herbal Products Association’s botanical safety handbook. Boca Raton: CRC Press; 1997.Google Scholar
  16. 16.
    Shimoda H, Tanaka J, Yamada E, et al. Anti type I allergic property of Japanese butterbur extract and its mast cell degranulation inhibitory ingredients. J Agric Food Chem. 2006;54:2915–20.CrossRefPubMedGoogle Scholar
  17. 17.
    Lipton RB, Göbel H, Einhäupl KM, et al. Petasites hybridus root (butterbur) is an effective preventive treatment for migraine. Neurology. 2004;63:2240–4.CrossRefPubMedGoogle Scholar
  18. 18.
    Diener HC, Rahlfs VW, Danesch U. The first placebo-controlled trial of a special butterbur root extract for the prevention of migraine: reanalysis of efficacy criteria. Eur Neurol. 2004;51:89–97.CrossRefPubMedGoogle Scholar
  19. 19.
    Tepper SJ. Evidence-based basics on neutraceutical herbs, minerals, vitamins and supplements in migraine management. https://americanheadachesociety.org/wp-content/uploads/2018/06/Tepper-Nutraceuticals.docx. Accessed Jun 2019.
  20. 20.
    Diener HC, Freitag FG, Danesch U. Safety profile of a special butterbur extract from Petasites hybridus in migraine prevention with emphasis on the liver. Cephalalgia Rep. 2018;1:1–8.  https://doi.org/10.1177/2515816318759304.CrossRefGoogle Scholar
  21. 21.
    Pittler MH, Ernst E. Feverfew for preventing migraine. Cochrane Database Syst Rev. 2004;CD002286.Google Scholar
  22. 22.
    Wider B, Pittler MH, Ernst E. Feverfew for preventing migraine. Cochrane Database Syst Rev. 2015;4:CD002286.PubMedGoogle Scholar
  23. 23.
    Delavar Kasmaei H, Ghorbanifar Z, Zayeri F, et al. Effects of Coriandrum sativum syrup on migraine: a randomized, triple-blind, placebo-controlled trial. Iran Red Crescent Med J. 2016;8(1):e20759.Google Scholar
  24. 24.
    Kamali M, Seifadini R, Kamali H, et al. Efficacy of combination of Viola odorata, Rosa damascena and Coriandrum sativum in prevention of migraine attacks: a randomized, double blind, placebo-controlled clinical trial. Electron Physician. 2018;10:6430–8.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Kasper S, Caraci F, Forti B, et al. Efficacy and tolerability of hypericum extract for the treatment of mild to moderate depression. Eur Neuropsychopharmacol. 2010;20(11):747–65.CrossRefPubMedGoogle Scholar
  26. 26.
    Borhani Haghighi A, Motazedian S, Rezaii R, et al. Cutaneous application of menthol 10% solution as an abortive treatment of migraine without aura: a randomised, double-blind, placebo-controlled, crossed-over study. Int J Clin Pract. 2010;64:451–6.CrossRefPubMedGoogle Scholar
  27. 27.
    Niazi M, Hashempur MH, Taghizadeh M, et al. Efficacy of topical Rose (Rosa damascena Mill) oil for migraine headache: a randomized double-blinded placebo-controlled cross-over trial. Complement Ther Med. 2017;34:35–41.CrossRefPubMedGoogle Scholar
  28. 28.
    Fan P. Cannabinoid agonists inhibit the activation of 5-HT3 receptors in rat nodose ganglion neurons. J Neurophysiol. 1995;73:907–10.CrossRefPubMedGoogle Scholar
  29. 29.
    Baron EP. Comprehensive review of medicinal marijuana, cannabinoids, and therapeutic implications in medicine and headache: what a long strange trip it’s been. Headache. 2015;55:885–916.CrossRefPubMedGoogle Scholar
  30. 30.
    Williamson EM, Evans FJ. Cannabinoids in clinical practice. Drugs. 2000;60:1303–14.CrossRefPubMedGoogle Scholar
  31. 31.
    Aggarwal SK. Cannabinergic pain medicine: a concise clinical primer and survey of randomized-controlled trial results. Clin J Pain. 2013;29:162–71.CrossRefPubMedGoogle Scholar
  32. 32.
    Zargaran A, Borhani-Haghighi A, Salehi-Marzijarani M, et al. Evaluation of the effect of topical chamomile (Matricaria chamomilla L.) oleogel as pain relief in migraine without aura: a randomized, double-blind, placebocontrolled, crossover study. Neurol Sci. 2018;39(8):1345–53.CrossRefPubMedGoogle Scholar
  33. 33.
    Galeotti N, Ghelardini C. St. John’s wort reversal of meningeal nociception: a natural therapeutic perspective for migraine pain. Phytomedicine. 2013;20:930–8.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Springer NatureAucklandNew Zealand

Personalised recommendations